583 related articles for article (PubMed ID: 18371465)
1. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II--study design and rationale.
Mehta RH; Alexander JH; Emery R; Ellis SJ; Hasselblad V; Khalil A; Carrier M; Harrington RA; Tardif JC;
Am Heart J; 2008 Apr; 155(4):600-8. PubMed ID: 18371465
[TBL] [Abstract][Full Text] [Related]
2. Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study.
Tardif JC; Carrier M; Kandzari DE; Emery R; Cote R; Heinonen T; Zettler M; Hasselblad V; Guertin MC; Harrington RA;
J Thorac Cardiovasc Surg; 2007 Jun; 133(6):1604-11. PubMed ID: 17532963
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial.
; Alexander JH; Emery RW; Carrier M; Ellis SJ; Mehta RH; Hasselblad V; Menasche P; Khalil A; Cote R; Bennett-Guerrero E; Mack MJ; Schuler G; Harrington RA; Tardif JC
JAMA; 2008 Apr; 299(15):1777-87. PubMed ID: 18381567
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery.
Carrier M; Ménasché P; Levy JH; Newman MF; Taylor KM; Haverich A; Chen JC; Shernan SK; Van de Werf F; van der Laan M; Todaro TG; Adams PX; Verrier ED
J Thorac Cardiovasc Surg; 2006 Feb; 131(2):352-6. PubMed ID: 16434264
[TBL] [Abstract][Full Text] [Related]
5. Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time.
Smith PK; Carrier M; Chen JC; Haverich A; Levy JH; Menasché P; Shernan SK; Van de Werf F; Adams PX; Todaro TG; Verrier E
Ann Thorac Surg; 2006 Sep; 82(3):781-8; discussion 788-9. PubMed ID: 16928483
[TBL] [Abstract][Full Text] [Related]
6. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.
Hueb W; Lopes NH; Gersh BJ; Soares P; Machado LA; Jatene FB; Oliveira SA; Ramires JA
Circulation; 2007 Mar; 115(9):1082-9. PubMed ID: 17339566
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of pyridoxal-5-phosphate (MC-1) on perioperative myocardial infarction is independent of aortic cross clamp time: results from the MEND-CABG trial.
Carrier M; Emery R; Kandzari DE; Harrington R; Guertin MC; Tardif JC
J Cardiovasc Surg (Torino); 2008 Apr; 49(2):249-53. PubMed ID: 18431346
[TBL] [Abstract][Full Text] [Related]
8. Ischemia Management with Accupril post bypass Graft via Inhibition of angiotensin coNverting enzyme (IMAGINE): a multicentre randomized trial - design and rationale.
Warnica JW; Gilst WV; Baillot R; Johnstone D; Block P; Myers MG; Chocron S; Ave SD; Martineau P; Rouleau JL
Can J Cardiol; 2002 Nov; 18(11):1191-200. PubMed ID: 12464983
[TBL] [Abstract][Full Text] [Related]
9. Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients.
Haverich A; Shernan SK; Levy JH; Chen JC; Carrier M; Taylor KM; Van de Werf F; Newman MF; Adams PX; Todaro TG; van der Laan M; Verrier ED
Ann Thorac Surg; 2006 Aug; 82(2):486-92. PubMed ID: 16863750
[TBL] [Abstract][Full Text] [Related]
10. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery.
Rouleau JL; Warnica WJ; Baillot R; Block PJ; Chocron S; Johnstone D; Myers MG; Calciu CD; Dalle-Ave S; Martineau P; Mormont C; van Gilst WH;
Circulation; 2008 Jan; 117(1):24-31. PubMed ID: 18071079
[TBL] [Abstract][Full Text] [Related]
11. The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.
Alexander JH; Ferguson TB; Joseph DM; Mack MJ; Wolf RK; Gibson CM; Gennevois D; Lorenz TJ; Harrington RA; Peterson ED; Lee KL; Califf RM; Kouchoukos NT;
Am Heart J; 2005 Oct; 150(4):643-9. PubMed ID: 16209958
[TBL] [Abstract][Full Text] [Related]
12. Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up.
Zaugg M; Bestmann L; Wacker J; Lucchinetti E; Boltres A; Schulz C; Hersberger M; Kälin G; Furrer L; Hofer C; Blumenthal S; Müller A; Zollinger A; Spahn DR; Borgeat A
Anesthesiology; 2007 Jul; 107(1):33-44. PubMed ID: 17585213
[TBL] [Abstract][Full Text] [Related]
13. Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials.
Smith PK; Datta SK; Muhlbaier LH; Samsa G; Nadel A; Lipscomb J
Ann Thorac Surg; 2004 Feb; 77(2):635-42; discussion 642-3. PubMed ID: 14759451
[TBL] [Abstract][Full Text] [Related]
14. Statin Recapture Therapy before Coronary Artery Bypass Grafting Trial: Rationale and study design of a multicenter, randomized, double-blinded controlled clinical trial.
Liakopoulos OJ; Kuhn EW; Hellmich M; Kuhr K; Krause P; Reuter H; Thurat M; Choi YH; Wahlers T;
Am Heart J; 2015 Jul; 170(1):46-54, 54.e1-2. PubMed ID: 26093863
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials.
Daemen J; Boersma E; Flather M; Booth J; Stables R; Rodriguez A; Rodriguez-Granillo G; Hueb WA; Lemos PA; Serruys PW
Circulation; 2008 Sep; 118(11):1146-54. PubMed ID: 18725490
[TBL] [Abstract][Full Text] [Related]
16. Deterioration of regional wall motion immediately after coronary artery bypass graft surgery is associated with long-term major adverse cardiac events.
Swaminathan M; Morris RW; De Meyts DD; Podgoreanu MV; Jollis JG; Grocott HP; Milano CA; Newman MF; Mathew JP
Anesthesiology; 2007 Nov; 107(5):739-45. PubMed ID: 18073549
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
[TBL] [Abstract][Full Text] [Related]
18. Comparison of drug-eluting stents and coronary artery bypass surgery for the treatment of multivessel coronary disease: three-year follow-up results from a single institution.
Li Y; Zheng Z; Xu B; Zhang S; Li W; Gao R; Hu S
Circulation; 2009 Apr; 119(15):2040-50. PubMed ID: 19349321
[TBL] [Abstract][Full Text] [Related]
19. Myocardial infarction following coronary artery bypass graft surgery increases healthcare resource utilization.
Chen JC; Kaul P; Levy JH; Haverich A; Menasché P; Smith PK; Carrier M; Verrier ED; Van de Werf F; Burge R; Finnegan P; Mark DB; Shernan SK;
Crit Care Med; 2007 May; 35(5):1296-301. PubMed ID: 17414091
[TBL] [Abstract][Full Text] [Related]
20. The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design.
Kapur A; Malik IS; Bagger JP; Anderson JR; Kooner JS; Thomas M; Punjabi P; Mayet J; Millane T; Goedicke J; Jamrozik K; de Belder MA; Hall RJ; Beatt KJ
Am Heart J; 2005 Jan; 149(1):13-9. PubMed ID: 15660030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
